Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May;77(5):678-683.
doi: 10.1136/annrheumdis-2017-212407. Epub 2017 Dec 15.

Preference phenotypes to facilitate shared decision-making in rheumatoid arthritis

Liana Fraenkel  1   2 , W Benjamin Nowell  3 , George Michel  1   2 , Carole Wiedmeyer  3
Affiliations

Preference phenotypes to facilitate shared decision-making in rheumatoid arthritis

Liana Fraenkel et al. Ann Rheum Dis. 2018 May.

Abstract

Objective: Implementing treat-to-target (TTT) strategies requires that patients with rheumatoid arthritis (RA) and their rheumatologists decide on how best to escalate care when indicated. The objective of this study was to develop preference phenotypes to facilitate shared decision-making at the point of care for patients failing methotrexate monotherapy.

Methods: We developed a conjoint analysis survey to measure the preferences of patient with RA for triple therapy, biologics and Janus kinase (JAK) inhibitors. The survey included seven attributes: administration, onset, bothersome side effects, serious infection, very rare side effects, amount of information and cost. Each choice set (n=12) included three hypothetical profiles. Preference phenotypes were identified by applying latent class analysis to the conjoint data.

Results: 1273 participants completed the survey. A five-group solution was chosen based on progressively lower values of the Akaike and Bayesian information criteria. Members of the largest group (group 3: 38.4%) were most strongly impacted by the cost of the medication. The next largest group (group 1: 25.8%) was most strongly influenced by the risk of bothersome side effects. Members of group 2 (11.2%) were also risk averse, but were most concerned with the risk of very rare side effects. Group 4 (6.6%) strongly preferred oral over parenteral medications. Members of group 5 (18.0%) were most strongly and equally influenced by onset of action and the risk of serious infections.

Conclusions: Treatment preferences of patients with RA can be measured and represented by distinct phenotypes. Our results underscore the variability in patients' values and the importance of using a shared decision-making approach to implement TTT.

Keywords: dmards (biologic); dmards (synthetic); patient perspective; rheumatoid arthritis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1. Example of a Choice Task
If these were your only options, which would you choose? Choose by clicking one of the buttons below. You can see more information by clicking on the medication facts in the left hand column.
Figure 2
Figure 2. Relative Importances per Cluster
Grey: Route of Administration Purple: Onset of Action Orange: Bothersome side effects Yellow: Risk of serious infection Red: Risk of serious, but rare side effect Green: Time available on the market Dark Blue: Cost (Affordability)
Figure 3
Figure 3. Preferences for Triple Therapy vs Subcutanteous Anti-TNF
Blue: Preference for Triple therapy Orange: Preference for Anti-TNF
Figure 4
Figure 4. Preferences for Lower Risk Triple Therapy vs Subcutaneous Anti-TNF
Blue: Preference for Triple therapy Orange: Preference for Anti-TNF
Figure 5
Figure 5. Preferences for Triple Therapy vs Less Costly Subcutaneous Anti-TNF
Blue: Preference for Triple therapy Orange: Preference for Anti-TNF
Figure 6
Figure 6. Preferences for Rituximab vs JAK Inhibitor
Blue: Preference for Rituximab Orange: Preference for JAK Inhibitor
See this image and copyright information in PMC

References

    1. Schwartz B. The paradox of choice: Why more is less. Revised. New York: Harper Collins; 2016.
    1. Iyengar SS, Lepper MR. When choice is demotivating: Can one desire too much of a good thing? J Person Soc Psychol. 2000;79:995–1006. - PubMed
    1. Shah AM, Wolford G. Buying behavior as a function of parametric variation of number of choices. Psychol Sci. 2007;18:369–70. - PubMed
    1. Oshima Lee E, Emanuel EJ. Shared decision making to improve care and reduce costs. N Engl J Med. 2013;368:6–8. - PubMed
    1. Stacey D, Legare F, Lewis K, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Of Systematic Reviews. 2017;4 Cd001431. - PMC - PubMed

Publication types